4-Hydroxy-Lumiracoxib | 220991-37-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Hydroxy-Lumiracoxib
• 英文别名: 5-methyl-2-(2'-chloro-4'-hydroxy-6'-fluoroanilino)phenylacetic acid；Lumiracoxib metabolite M23；2-[2-(2-chloro-6-fluoro-4-hydroxyanilino)-5-methylphenyl]acetic acid
• CAS: 220991-37-7
• 化学式: C₁₅H₁₃ClFNO₃
• 分子量: 309.725
• InChiKey: LUNFHOZKXHTOLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  5

ADMET

代谢

4p-羧基米拉考昔已知的人体代谢物包括卢米拉考昔M22。

4p-Carboxylumiracoxib has known human metabolites that include Lumiracoxib M22.

来源:NORMAN Suspect List Exchange

反应信息

• 作为产物：
  描述：

  2-chloro-4-pivaloyloxy-6-fluoroaniline 生成 4-Hydroxy-Lumiracoxib
  参考文献：
  名称：

  Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

  摘要：

  公开的是以下式I的化合物 其中R是甲基或乙基；R1是氯或氟；R2是氢或氟；R3是氢、氟、氯、甲基、乙基、甲氧基、乙氧基或羟基；R4是氢或氟；R5是氯、氟、三氟甲基或甲基；以及其药学上可接受的盐，作为选择性COX-2环氧合酶抑制剂；以及其药学上可接受的前药酯。

  公开号：

  US06291523B1

文献信息

• Process for phenylacetic acid derivatives
  申请人：Acemoglu Murat

  公开号：US20080249318A1

  公开（公告）日：2008-10-09

  A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.

  生产Formula I化合物或其药用可接受盐或其药用可接受的前药酯的过程，包括用碱裂解Formula II的内酰胺，其中符号的定义如上；以及前体和前体的制备过程。Formula I化合物是具有药理活性的化合物，是环氧合酶II的选择性抑制剂。
• [EN] PROCESS FOR PHENYLACETIC ACID DERIVATIVES<br/>[FR] PROCEDES DE PRODUCTION DE PRODUITS DERIVES D'ACIDES PHENYLACETIQUES
  申请人：NOVARTIS AG

  公开号：WO2001023346A2

  公开（公告）日：2001-04-05

  A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula (II) wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of formula (I) are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase (II).

  一种生产式(I)化合物、其药学上可接受的盐或药学上可接受的前药酯的方法，包括用碱水解式(II)内的内酰胺，其中符号如定义的；以及其前体和制备前体的方法。式(I)化合物是具有药学活性的化合物，是环氧合酶(II)的选择性抑制剂。
• PROCESS FOR PHENYLACETIC ACID DERIVATIVES
  申请人：Acemoglu Murat

  公开号：US20090275758A1

  公开（公告）日：2009-11-05

  A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.

  一种制备I式化合物或其药学上可接受的盐或药学上可接受的前药酯的方法，包括用碱水解II式内酰胺，其中符号的定义如下；以及其前体和前体的制备方法。I式化合物是具有药理活性的化合物，是环氧合酶II的选择性抑制剂。
• [EN] CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES<br/>[FR] CERTAINS ACIDES 5-ALKYL-2-ARYLAMINOPHENYLACETIQUES ET LEURS DERIVES
  申请人：NOVARTIS AG

  公开号：WO1999011605A1

  公开（公告）日：1999-03-11

  Disclosed are the compounds of formula (I), wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; as selective COX-2 cyclooxygenase inhibitors.

  本发明涉及式（I）的化合物，其中R为甲基或乙基；R1为氯或氟；R2为氢或氟；R3为氢、氟、氯、甲基、乙基、甲氧基、乙氧基或羟基；R4为氢或氟；R5为氯、氟、三氟甲基或甲基；其药学上可接受的盐；及其药学上可接受的前药酯，作为选择性COX-2环氧化酶抑制剂。
• Certain 5-alkyl-2arylaminophenylacetic acids and derivatives
  申请人：——

  公开号：US20020013369A1

  公开（公告）日：2002-01-31

  Disclosed are the compounds of formula I 1 wherein R is methyl or ethyl; R 1 is chloro or fluoro; R 2 is hydrogen or fluoro; R 3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R 4 is hydrogen or fluoro; and R 5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.

  本发明涉及一种化合物，其化学式为I1，其中R为甲基或乙基；R1为氯或氟；R2为氢或氟；R3为氢、氟、氯、甲基、乙基、甲氧基、乙氧基或羟基；R4为氢或氟；R5为氯、氟、三氟甲基或甲基；以及其药学上可接受的盐，作为选择性COX-2环氧化酶抑制剂；以及其药学上可接受的前药酯。